Personalized Nutrition: Global Markets
個別化栄養: 世界市場
Report Highlights
The global personalized nutrition market reached $12.2 billion in 2022 and should reach $25.1 billion by 2028, with a compound annual growth rate (CAGR) of 12.5% during the forecast period of 2023-2028.
Report Synopsis
| Report Metrics | Details |
|---|---|
| Base year considered | 2023 |
| Forecast period considered | 2023-2028 |
| Base year market size | $13.9 billion |
| Market size forecast | $25.1 billion |
| Growth rate | CAGR of 12.5% for the forecast period of 2023-2028 |
| Units considered | $ Millions |
| Segments covered | Component Type, Assessment Type, Supplement Type, Channel Type, Region |
| Regions covered | North America, Europe, Asia-Pacific, Rest of the World (RoW) |
| Countries covered | U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, Russia, Sweden, Austria, Netherlands, Norway, China, India, Japan, South Korea, Australia, New Zealand, Malaysia, Indonesia, Taiwan, Singapore, South America, Middle East, Africa |
| Key Market Drivers |
|
| Companies studied | AMWAY CORP. , ATLAS BIOMED GROUP LIMITED , BACTOLAC PHARMACEUTICAL INC. , BALCHEM CORP. , CUREFIT HEALTHCARE PRIVATE LIMITED , DAYTWO INC. , DNALYSIS BIOTECHNOLOGY , GENOPLAN INC. , HEALTHIFYME WELLNESS PRIVATE LIMITED , HERBALIFE NUTRITION LTD. , KONINKLIJKE DSM N.V. , MYGENOMEBOX CORP. , NOHO HEALTH INC. , NUTRIGENOMIX , PRENETICS EMEA LIMITED , VIOME LIFE SCIENCES INC. , ZIPONGO INC. , ZYWIE VENTURES PRIVATE LIMITED |